Company: PRTA
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001559053-25-000031
Chunk: 0

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
 12,383  
  Issuance of ordinary shares upon exercise of stock options          38,338      —           890                                              890                                  
  Net loss                                                                                                                      ( 72,239)                                ( 72,239)  
  Balances at March 31, 2024                                      53,720,455      537                         1,554,132      ( 1,052,270)                                  502,399  
  Share-based compensation                                                                                       12,041                                                     12,041  
  Issuance of ordinary shares upon exercise of stock options          51,390      1           590                                              591                                  
  Net income                                                                                                                       66,886                                   66,886  
  Balances at June 30, 2024                                       53,771,845      $           $               1,566,763        ( 985,384)      $                           581,917  

See accompanying Notes to Condensed Consolidated Financial Statements.

Notes to the Condensed Consolidated Financial Statements

(unaudited)

1. Organization

Description of Business

Prothena Corporation plc (“ Prothena” or the “ Company”) is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases.

Fueled by its deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. The Company’s wholly-owned programs include a portfolio of programs for the potential treatment of Alzheimer’s disease including PRX012, which targets amyloid beta (Aβ) and PRX123, a novel dual Aβ-tau vaccine. The Company’s partnered programs include prasinezumab for the potential treatment of Parkinson’s disease and other related synucleinopathies that targets alpha-synuclein in collaboration with Roche. In addition, we have partnered BMS-986446 (formerly PRX005) for the potential treatment of Alzheimer’s disease that targets tau and PRX019 for the potential treatment of neurodegenerative diseases with an undisclosed target in two separate license agreements with Bristol Myers Squibb (“ BMS”). The Company is also entitled to certain potential milestone payments pursuant to the Company’s share purchase agreement with Novo